Industry incentives and antibiotic resistance

In the face of increasing drug resistance, there is a pressing need to develop new antibiotic compounds. However, the effort of developing such new treatments can go unrewarded, so long as there are still cheaper options in current supply, even as their effectiveness wanes. Olof Lindahl and Chantal Morel review the business interventions, stewardship policies and prescription practices available to incentivise the development of new medicines, and thus support global health.Find out more about their work at  https://www.jpiamr.eu/Read the original article: https://doi.org/10.1038/s41429-020-0300-y